Atlas FDA

VERSANT HCV Genotype 2.0 Assay (LiPA)

FDA premarket approval P160016/S001 · decided 2018-02-08

Approval details

PMA number
P160016
Supplement
S001
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
VERSANT HCV Genotype 2.0 Assay (LiPA)
Generic name
Assay, genotyping, hepatitis c virus
Applicant
Fujirebio Europe N.V.
Date received
2018-01-02
Decision date
2018-02-08
Days to decision
37 days
Decision code
APPR
Product code
OBF
Advisory committee
Microbiology
Expedited review
No
Location
Gent
Statement
Approval for a modification to the assay procedure to allow the VERSANT kPCR Molecular System Sample Preparation module to automatically set up the PCR plate following the RNA extraction step.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.